CMIC HOLDINGS Co., Ltd. Action · JP3359000001 (XTKS) — cotations en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

CMIC HOLDINGS Co., Ltd. provides various services for the pharmaceutical industry in Japan. The company operates in five segments: Contract Research Organization, Contract Development and Manufacturing Organization, Contract Sales Organization, Healthcare, and Innovative Pharma Model. It offers clinical trial services, including clinical operations and trials, data management, clinical caretaker, medical writing, patient recruitment, pharmacovigilance, project management, audit and quality assurance, and statistical analysis; and clinical site network, CMC, drug development, health economics and outcome research, market entry/out-licensing, medical devices and in vitro diagnostic consulting, medical writing, national health insurance pricing, and product life cycle management consulting services. The company also provides development and manufacturing services, including commercial supply, contract development and manufacturing, investigational product manufacturing, packaging and labeling, release and stability tests, technology transfer, as well as formulation, process, and analytical development services; and laboratory services, such as bioanalysis and GLP analysis, biomarkers, CMC and GMP analysis, large molecule, oligonucleotides, small molecule, and toxicity, as well as safety pharmacology, in vitro and in vivo, and non-clinical studies. In addition, it offers patient and healthcare services, such as drug adherence support program, harmo, Helc+, prescription drug database, and selcheck services; and post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing, clinical research coordinating, clinical site administration, and site management services. CMIC HOLDINGS Co., Ltd. has a partnership with Science 37, Inc. to decentralize clinical trials and enhance the development of treatments. The company was incorporated in 1985 and is headquartered in Tokyo, Japan.